Cromolyn sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413352

CAS#: 15826-37-6 (sodium)

Description: Cromolyn sodium is a chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.


Chemical Structure

img
Cromolyn sodium
CAS# 15826-37-6 (sodium)

Theoretical Analysis

MedKoo Cat#: 413352
Name: Cromolyn sodium
CAS#: 15826-37-6 (sodium)
Chemical Formula: C23H14Na2O11
Exact Mass: 0.00
Molecular Weight: 512.330
Elemental Analysis: C, 53.92; H, 2.75; Na, 8.97; O, 34.35

Price and Availability

Size Price Availability Quantity
1g USD 350 2 Weeks
5g USD 750 2 Weeks
25g USD 1250 2 Weeks
Bulk inquiry

Related CAS #: 16110-51-3 (free acid)   5826-37-6 (sodium hydrate)   107032-81-5 (sulfate)   15826-37-6 (sodium)  

Synonym: Cromolyn sodium; Disodium Cromoglycate; CCRIS3194; CCRIS-3194; CCRIS 3194

IUPAC/Chemical Name: 4H-1-Benzopyran-2-carboxylic acid, 5,5'-((2-hydroxy-1,3-propanediyl)bis(oxy))bis(4-oxo-, disodium salt

InChi Key: VLARUOGDXDTHEH-UHFFFAOYSA-L

InChi Code: InChI=1S/C23H16O11.2Na/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30;;/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30);;/q;2*+1/p-2

SMILES Code: OC(COC1=C2C(C=C(C([O-])=O)OC2=CC=C1)=O)COC3=C4C(C=C(C([O-])=O)OC4=CC=C3)=O.[Na+].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target: Cromolyn sodium is a GSK-3β inhibitor with an IC50 of 2.0 µM.
In vitro activity: This study then tested the effect of both cromolyn and F-cromolyn at a low (0.3 µM) and higher (3 µM) concentration against TNF-α induced cytokine secretion by HMC3 microglia. IFN-γ (p = 0.0033; p = 0.0013), IL-6 (p = 0.0065; p = 0.0012), IL-1β (p < 0.001; p < 0.001), and IL-8 (p = 0.0006; p < 0.001) concentrations were decreased after addition of the lower 0.3 µM concentration of cromolyn and F-cromolyn, respectively, with only cromolyn dose-dependently reducing IL-6 (p < 0.001) and IL-1β (p < 0.001) after 3 µM addition. Reference: Sci Rep. 2021; 11: 8054. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044132/
In vivo activity: There was a significant effect of treatment on peak body weight (Mantel-Cox test, p < 0.0001), with a median age of onset of 110 days for TgSOD1-Vehicle group and 130 days for the TgSOD1-Cromolyn group (Fig. 1b). These findings suggest that cromolyn treatment delayed disease onset in TgSOD1 mice. Male and female data are shown separately in Fig, S1a,b. Both female mice (Mantel-Cox test, p = 0.0009) (Fig. S1a) and male mice (Mantel-Cox test, p = 0.0193) (Fig. S1b) demonstrated a significant delay in the onset of motor symptoms following cromolyn treatment. Reference: Sci Rep. 2019; 9: 17728. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881366/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 25.0 48.80
Water 25.9 50.49

Preparing Stock Solutions

The following data is based on the product molecular weight 512.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Wang YJ, Monteagudo A, Downey MA, Ashton-Rickardt PG, Elmaleh DR. Cromolyn inhibits the secretion of inflammatory cytokines by human microglia (HMC3). Sci Rep. 2021 Apr 13;11(1):8054. doi: 10.1038/s41598-021-85702-8. PMID: 33850164; PMCID: PMC8044132. 2. Zhang C, Griciuc A, Hudry E, Wan Y, Quinti L, Ward J, Forte AM, Shen X, Ran C, Elmaleh DR, Tanzi RE. Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis. Sci Rep. 2018 Jan 18;8(1):1144. doi: 10.1038/s41598-018-19641-2. PMID: 29348604; PMCID: PMC5773545. 3. Granucci EJ, Griciuc A, Mueller KA, Mills AN, Le H, Dios AM, McGinty D, Pereira J, Elmaleh D, Berry JD, Paganoni S, Cudkowicz ME, Tanzi RE, Sadri-Vakili G. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Sci Rep. 2019 Nov 27;9(1):17728. doi: 10.1038/s41598-019-53982-w. PMID: 31776380; PMCID: PMC6881366. 4. Jiang L, Fang P, Septer S, Apte U, Pritchard MT. Inhibition of Mast Cell Degranulation With Cromolyn Sodium Exhibits Organ-Specific Effects in Polycystic Kidney (PCK) Rats. Int J Toxicol. 2018 Jul/Aug;37(4):308-326. doi: 10.1177/1091581818777754. Epub 2018 Jun 3. PMID: 29862868; PMCID: PMC6027616.
In vitro protocol: 1. Wang YJ, Monteagudo A, Downey MA, Ashton-Rickardt PG, Elmaleh DR. Cromolyn inhibits the secretion of inflammatory cytokines by human microglia (HMC3). Sci Rep. 2021 Apr 13;11(1):8054. doi: 10.1038/s41598-021-85702-8. PMID: 33850164; PMCID: PMC8044132. 2. Zhang C, Griciuc A, Hudry E, Wan Y, Quinti L, Ward J, Forte AM, Shen X, Ran C, Elmaleh DR, Tanzi RE. Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis. Sci Rep. 2018 Jan 18;8(1):1144. doi: 10.1038/s41598-018-19641-2. PMID: 29348604; PMCID: PMC5773545.
In vivo protocol: 1. Granucci EJ, Griciuc A, Mueller KA, Mills AN, Le H, Dios AM, McGinty D, Pereira J, Elmaleh D, Berry JD, Paganoni S, Cudkowicz ME, Tanzi RE, Sadri-Vakili G. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Sci Rep. 2019 Nov 27;9(1):17728. doi: 10.1038/s41598-019-53982-w. PMID: 31776380; PMCID: PMC6881366. 2. Jiang L, Fang P, Septer S, Apte U, Pritchard MT. Inhibition of Mast Cell Degranulation With Cromolyn Sodium Exhibits Organ-Specific Effects in Polycystic Kidney (PCK) Rats. Int J Toxicol. 2018 Jul/Aug;37(4):308-326. doi: 10.1177/1091581818777754. Epub 2018 Jun 3. PMID: 29862868; PMCID: PMC6027616.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bernstein IL. Cromolyn sodium. Chest. 1985 Jan;87(1 Suppl):68S-73S. doi: 10.1378/chest.87.1_supplement.68s. PMID: 3917246.

2: Shapiro GG, König P. Cromolyn sodium: a review. Pharmacotherapy. 1985 May- Jun;5(3):156-70. doi: 10.1002/j.1875-9114.1985.tb03412.x. PMID: 3927266.

3: Bernstein IL, Johnson CL. Therapy with cromolyn sodium. Ann Intern Med. 1978 Aug;89(2):228-33. doi: 10.7326/0003-4819-89-2-228. PMID: 98084.

4: Storms W, Kaliner MA. Cromolyn sodium: fitting an old friend into current asthma treatment. J Asthma. 2005 Mar;42(2):79-89. PMID: 15871438.

5: Murphy S, Kelly HW. Cromolyn sodium: a review of mechanisms and clinical use in asthma. Drug Intell Clin Pharm. 1987 Jan;21(1 Pt 1):22-35. doi: 10.1177/10600280870211p102. PMID: 3102198.

6: Falliers CJ. Cromolyn sodium (disodium cromoglycate) prophylaxis. Pediatr Clin North Am. 1975 Feb;22(1):141-6. doi: 10.1016/s0031-3955(16)33109-1. PMID: 49874.

7: Brogden RN, Speight TM, Avery GS. Sodium cromoglycate (cromolyn sodium). II. Allergic rhinitis and other conditions. Drugs. 1974;7(3):283-96. doi: 10.2165/00003495-197407030-00003. PMID: 4153068.

8: Brogden RN, Speight TM, Avery GS. Sodium cromoglycate (cromolyn sodium): a review of its mode of action, pharmacology, therapeutic efficacy and use. Drugs. 1974;7(3):164-282. doi: 10.2165/00003495-197407030-00002. PMID: 4212341.

9: Zur E. Topical use of sodium cromoglicate (cromolyn sodium) to treat atopic dermatitis and other skin allergies. Int J Pharm Compd. 2012 Sep- Oct;16(5):386-93. PMID: 23072198.

10: König P, Grigg CF. Cromolyn sodium or nedocromil in childhood asthma: does it matter? Clin Exp Allergy. 2000 Feb;30(2):164-71. doi: 10.1046/j.1365-2222.2000.00689.x. PMID: 10651767.